Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name CDKN2A hypermethylation
Gene Variant Detail

CDKN2A hypermethylation (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CDKN2A hypermethylation colorectal cancer not applicable N/A Clinical Study - Meta-analysis Prognostic In a meta-analysis, CDKN2A promoter hypermethylation was associated with poor overall survival (HR=1.65, 95% CI 1.29-2.11), lymphovascular invasion (OR=1.68, 95% CI 1.15-2.47), and lymph node metastasis (OR=1.68, 95% CI 1.09-2.59) in colorectal cancer patients, and correlated significantly with poor overall survival in patients from Europe (HR=1.49, 95% CI 1.28-1.74) and Asia (HR=3.30, 95% CI 1.68-6.46) (PMID: 23703248). 23703248
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries